Literature DB >> 28476208

Transcriptome Alterations in Prefrontal Pyramidal Cells Distinguish Schizophrenia From Bipolar and Major Depressive Disorders.

Dominique Arion1, Zhiguang Huo2, John F Enwright1, John P Corradi3, George Tseng2, David A Lewis4.   

Abstract

BACKGROUND: Impairments in certain cognitive processes (e.g., working memory) are typically most pronounced in schizophrenia (SZ), intermediate in bipolar disorder, and least in major depressive disorder. Given that working memory depends, in part, on neural circuitry that includes pyramidal cells in layer 3 (L3) and layer 5 (L5) of the dorsolateral prefrontal cortex (DLPFC), we sought to determine if transcriptome alterations in these neurons were shared or distinctive for each diagnosis.
METHODS: Pools of L3 and L5 pyramidal cells in the DLPFC were individually captured by laser microdissection from 19 matched tetrads of unaffected comparison subjects and subjects with SZ, bipolar disorder, and major depressive disorder, and the messenger RNA was subjected to transcriptome profiling by microarray.
RESULTS: In DLPFC L3 and L5 pyramidal cells, transcriptome alterations were numerous in subjects with SZ, but rare in subjects with bipolar disorder and major depressive disorder. The leading molecular pathways altered in subjects with SZ involved mitochondrial energy production and the regulation of protein translation. In addition, we did not find any significant transcriptome signatures related to psychosis or suicide.
CONCLUSIONS: In concert, these findings suggest that molecular alterations in DLPFC L3 and L5 pyramidal cells might be characteristic of the disease processes operative in individuals diagnosed with SZ and thus might contribute to the circuitry alterations underlying cognitive dysfunction in individuals with SZ.
Copyright © 2017 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Major depression; Microarray; Prefrontal cortex; Pyramidal neurons; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28476208      PMCID: PMC5610065          DOI: 10.1016/j.biopsych.2017.03.018

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  48 in total

1.  Transcriptome alterations in the prefrontal cortex of subjects with schizophrenia who committed suicide.

Authors:  Krassimira Garbett; Rodica Gal-Chis; Gabor Gaszner; David A Lewis; Károly Mirnics
Journal:  Neuropsychopharmacol Hung       Date:  2008-03

Review 2.  Cellular basis of working memory.

Authors:  P S Goldman-Rakic
Journal:  Neuron       Date:  1995-03       Impact factor: 17.173

3.  Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

Authors:  Glenn T Konopaske; Nicholas Lange; Joseph T Coyle; Francine M Benes
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

4.  Cognitive endophenotypes of psychosis within dimension and diagnosis.

Authors:  Elena I Ivleva; David W Morris; Julian Osuji; Amanda F Moates; Thomas J Carmody; Gunvant K Thaker; Munro Cullum; Carol A Tamminga
Journal:  Psychiatry Res       Date:  2012-02-18       Impact factor: 3.222

Review 5.  Working memory dysfunction in schizophrenia.

Authors:  P S Goldman-Rakic
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1994       Impact factor: 2.198

Review 6.  Dendritic spine pathology in schizophrenia.

Authors:  J R Glausier; D A Lewis
Journal:  Neuroscience       Date:  2012-04-27       Impact factor: 3.590

7.  Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.

Authors:  Dibyadeep Datta; Dominique Arion; John P Corradi; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-04-11       Impact factor: 13.382

Review 8.  Meta-analysis of Cognitive Impairment in First-Episode Bipolar Disorder: Comparison With First-Episode Schizophrenia and Healthy Controls.

Authors:  Emre Bora; Christos Pantelis
Journal:  Schizophr Bull       Date:  2015-01-23       Impact factor: 9.306

9.  Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders.

Authors:  Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet
Journal:  Schizophr Bull       Date:  2008-05-20       Impact factor: 9.306

Review 10.  ROS and brain diseases: the good, the bad, and the ugly.

Authors:  Aurel Popa-Wagner; Smaranda Mitran; Senthilkumar Sivanesan; Edwin Chang; Ana-Maria Buga
Journal:  Oxid Med Cell Longev       Date:  2013-12-05       Impact factor: 6.543

View more
  35 in total

1.  Markers of glutamate and GABA neurotransmission in the prefrontal cortex of schizophrenia subjects: Disease effects differ across anatomical levels of resolution.

Authors:  Samuel J Dienel; John F Enwright; Gil D Hoftman; David A Lewis
Journal:  Schizophr Res       Date:  2019-07-08       Impact factor: 4.939

2.  The 7q11.23 Protein DNAJC30 Interacts with ATP Synthase and Links Mitochondria to Brain Development.

Authors:  Andrew T N Tebbenkamp; Luis Varela; Jinmyung Choi; Miguel I Paredes; Alice M Giani; Jae Eun Song; Matija Sestan-Pesa; Daniel Franjic; André M M Sousa; Zhong-Wu Liu; Mingfeng Li; Candace Bichsel; Marco Koch; Klara Szigeti-Buck; Fuchen Liu; Zhuo Li; Yuka I Kawasawa; Constantinos D Paspalas; Yann S Mineur; Paolo Prontera; Giuseppe Merla; Marina R Picciotto; Amy F T Arnsten; Tamas L Horvath; Nenad Sestan
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

Review 3.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

4.  Diagnosis- and Cell Type-Specific Mitochondrial Functional Pathway Signatures in Schizophrenia and Bipolar Disorder.

Authors:  Jill R Glausier; John F Enwright; David A Lewis
Journal:  Am J Psychiatry       Date:  2020-10-29       Impact factor: 18.112

5.  Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia.

Authors:  Radhika Chadha; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2020-01-17       Impact factor: 7.853

Review 6.  Alterations in cortical interneurons and cognitive function in schizophrenia.

Authors:  Samuel J Dienel; David A Lewis
Journal:  Neurobiol Dis       Date:  2018-06-22       Impact factor: 5.996

7.  Suppression of Parvalbumin Interneuron Activity in the Prefrontal Cortex Recapitulates Features of Impaired Excitatory/Inhibitory Balance and Sensory Processing in Schizophrenia.

Authors:  Oana Toader; Moritz von Heimendahl; Niklas Schuelert; Wiebke Nissen; Holger Rosenbrock
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

8.  Unique Molecular Regulation of Higher-Order Prefrontal Cortical Circuits: Insights into the Neurobiology of Schizophrenia.

Authors:  Dibyadeep Datta; Amy F T Arnsten
Journal:  ACS Chem Neurosci       Date:  2018-03-01       Impact factor: 4.418

Review 9.  The origin of NMDA receptor hypofunction in schizophrenia.

Authors:  Kazu Nakazawa; Kiran Sapkota
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

10.  Profiling gene expression in the human dentate gyrus granule cell layer reveals insights into schizophrenia and its genetic risk.

Authors:  Andrew E Jaffe; Daniel J Hoeppner; Takeshi Saito; Lou Blanpain; Joy Ukaigwe; Emily E Burke; Leonardo Collado-Torres; Ran Tao; Katsunori Tajinda; Kristen R Maynard; Matthew N Tran; Keri Martinowich; Amy Deep-Soboslay; Joo Heon Shin; Joel E Kleinman; Daniel R Weinberger; Mitsuyuki Matsumoto; Thomas M Hyde
Journal:  Nat Neurosci       Date:  2020-03-16       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.